[jfollo]

Recent breakthroughs in the treatment of chronic lymphocytic leukemia (CLL) include the development of targeted therapies, such as new generations of ibrutinib and venetoclax, which are designed to target specific proteins that drive the growth and survival of CLL cells. These therapies have been shown to be highly effective in improving progression-free survival and overall survival in patients with CLL. Additionally, several new treatments are being investigated in clinical trials, including CAR-T cell therapy, which involves genetically modifying a patient's own T cells to target and kill cancer cells, and the use of bispecific antibodies, which are designed to bind to both cancer cells and immune cells to enhance the immune response against the cancer. These new treatments are showing promising results and are considered promising new therapies for CLL.

Interestingly, new research is showing that these new treatment modes may actually be as effective or more effective in IGHV unmutated patients as opposed to IGHV mutated patients. More data is needed and is on the way!